全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Supplementation with High Doses of Vitamin D to Subjects without Vitamin D Deficiency May Have Negative Effects: Pooled Data from Four Intervention Trials in Troms?

DOI: 10.1155/2013/348705

Full-Text   Cite this paper   Add to My Lib

Abstract:

Data were pooled from four randomized clinical trials with vitamin D performed in Troms? with weight reduction, insulin sensitivity, bone density, and depression scores as endpoints. Serum lipids, glycated hemoglobin ( ), and high sensitivity C-Reactive Protein, (HS-CRP) were measured at baseline and after 6–12 months of supplementation with vitamin D?20?000?IU–40?000?IU per week versus placebo. A total of 928 subjects who completed the interventions were included. At baseline the mean serum 25-hydroxyvitamin D (25(OH)D) level in those given vitamin D was 55.9 (20.9)?nmol/L and the mean increase was 82.4 (40.1)?nmol/L. Compared with the placebo group there was in the vitamin D group at the end of the studies a slight, but significant, increase in of 0.04%, an increase in HS-CRP of 0.07?mg/L in those with serum 25(OH)D <?50?nmol/L, and in those with low baseline HDL-C and serum 25(OH)D <?50?nmol/L a slight decrease serum HDL-C of 0.08 mmol/L ( ). No serious side-effects were seen. In conclusion, in subjects without vitamin D deficiency, there is no improvement in serum lipids, , or HS-CRP with high dose vitamin D supplementation. If anything, the effect is negative. 1. Introduction In recent years there has been a great interest in the relation between vitamin D and health outcomes [1]. As the vitamin D receptor (VDR) is found in tissues throughout the body it is reasonable to assume that effects of vitamin D are not restricted to its classical effects on calcium metabolism [2]. Thus, the levels of serum 25-hydroxyvitamin D (25(OH)D), which is the metabolite used to evaluate a subject’s vitamin D status [2], are in cross-sectional studies associated with risk factors for type 2 diabetes (T2DM) and cardiovascular disease [3–7] and in prospective studies associated with increased risk of these diseases and also cancer and even death [1, 8–11]. One would therefore expect that it should be easy to demonstrate a positive effect of vitamin D supplementation on health, but so far the evidence from properly performed randomized clinical trials (RCTs) is lacking. We have previously performed four large RCTs with high dose vitamin D intervention in Troms?, northern Norway, studying specifically the effects on weight [12], insulin sensitivity [13], bone density [14], and depression scores [15]. In addition to these endpoints we have also included other measures of glucose and lipid metabolism and inflammation markers. We have included more than 900 subjects in these studies, a number high enough to disclose an effect on these secondary endpoints, if present.

References

[1]  M. F. Holick, “Medical progress: vitamin D deficiency,” The New England Journal of Medicine, vol. 357, no. 3, pp. 266–281, 2007.
[2]  H. F. DeLuca, “Overview of general physiologic features and functions of vitamin D,” American Journal of Clinical Nutrition, vol. 80, no. 6, supplement, pp. 1689S–1696S, 2004.
[3]  R. Jorde, Y. Figenschau, N. Emaus, M. Hutchinson, and G. Grimnes, “Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension,” Hypertension, vol. 55, no. 3, pp. 792–798, 2010.
[4]  R. Jorde, M. Sneve, N. Emaus, Y. Figenschau, and G. Grimnes, “Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Troms? study,” European Journal of Nutrition, vol. 49, no. 7, pp. 401–407, 2010.
[5]  R. Jorde, Y. Figenschau, M. Hutchinson, N. Emaus, and G. Grimnes, “High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile,” European Journal of Clinical Nutrition, vol. 64, no. 12, pp. 1457–1464, 2010.
[6]  M. S. Hutchinson, Y. Figenschau, I. Nj?lstad, H. Schirmer, and R. Jorde, “Serum 25-hydroxyvitamin D levels are inversely associated with glycated haemoglobin (HbA1c). The Troms? Study,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 71, no. 5, pp. 399–406, 2011.
[7]  E. Hypp?nen, D. Berry, M. Cortina-Borja, and C. Power, “25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British Birth Cohort,” PloS ONE, vol. 5, no. 5, Article ID e10801, 2010.
[8]  L. Wang, Y. Song, J. E. Manson et al., “Circulating 25-Hydroxy-Vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies,” Circulation, vol. 5, no. 6, pp. 819–829, 2012.
[9]  Y. Ma, P. Zhang, F. Wang, J. Yang, Z. Liu, and H. Qin, “Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies,” Journal of Clinical Oncology, vol. 29, no. 28, pp. 3775–3782, 2011.
[10]  A. Zittermann, S. Iodice, S. Pilz, W. B. Grant, V. Bagnardi, and S. Gandini, “Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies,” American Journal of Clinical Nutrition, vol. 95, no. 1, pp. 91–100, 2012.
[11]  M. S. Hutchinson, G. Grimnes, R. M. Joakimsen, Y. Figenschau, and R. Jorde, “Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Troms? study,” European Journal of Endocrinology, vol. 162, no. 5, pp. 935–942, 2010.
[12]  M. Sneve, Y. Figenschau, and R. Jorde, “Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects,” European Journal of Endocrinology, vol. 159, no. 6, pp. 675–684, 2008.
[13]  G. Grimnes, Y. Figenschau, B. Alm?s, and R. Jorde, “Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique,” Diabetes, vol. 60, no. 11, pp. 2748–2757, 2011.
[14]  G. Grimnes, R. Joakimsen, Y. Figenschau, P. A. Torjesen, B. Alm?s, and R. Jorde, “The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial,” Osteoporosis International, vol. 23, no. 1, pp. 201–211, 2012.
[15]  M. Kj?rgaard, K. Waterloo, C. E. A. Wang et al., “Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial,” British Journal of Psychiatry, vol. 201, no. 5, pp. 360–368, 2012.
[16]  R. Jorde and G. Grimnes, “Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids,” Progress in Lipid Research, vol. 50, no. 4, pp. 303–312, 2011.
[17]  H. Wang, N. Xia, Y. Yang, and D.-Q. Peng, “Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials,” Lipids in Health and Disease, vol. 11, article 42, 2012.
[18]  M. P. Ponda, X. Huang, M. A. Odeh, J. L. Breslow, and H. W. Kaufman, “Vitamin D may not improve lipid levels: a serial clinical laboratory data study,” Circulation, vol. 126, no. 3, pp. 270–277, 2012.
[19]  R. Jorde and G. Grimnes, “Vitamin D and lipids: do we really need more studies?” Circulation, vol. 126, no. 3, pp. 252–254, 2012.
[20]  P. R. Von Hurst, W. Stonehouse, and J. Coad, “Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial,” British Journal of Nutrition, vol. 103, no. 4, pp. 549–555, 2010.
[21]  P. S. George, E. R. Pearson, and M. D. Witham, “Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis,” Diabetic Medicine, vol. 29, no. 8, pp. e142–e150, 2012.
[22]  A. D. Wood, K. R. Secombes, F. Thies et al., “Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 10, pp. 3557–3567, 2012.
[23]  A. D. Gepner, R. Ramamurthy, D. C. Krueger, and C. E. Korcarz, “A prospective randomized controlled trial of the effects of Vitamin D supplementation on cardiovascular disease risk,” PLoS ONE, vol. 7, no. 5, Article ID e36617, 2012.
[24]  R. Jorde, M. Sneve, P. A. Torjesen, Y. Figenschau, L. G. Goslash;ransson, and R. Omdal, “No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects,” Cytokine, vol. 50, no. 2, pp. 175–180, 2010.
[25]  L. Rejnmark, A. Avenell, T. Masud, et al., “Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 8, pp. 2670–2681, 2012.
[26]  S. Pilz, K. Kienreich, A. Tomaschitz et al., “Vitamin D and cardiovascular disease: update and outlook,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 243, pp. 83–91, 2012.
[27]  K. Kupferschmidt, “Uncertain verdict as vitamin D goes on trial,” Science, vol. 337, no. 6101, pp. 1476–1478, 2012.
[28]  N. M. Van Schoor and P. Lips, “Worldwide vitamin D status,” Best Practice and Research, vol. 25, no. 4, pp. 671–680, 2011.
[29]  S. Pilz, F. Rutters, and J. M. Dekker, “Disease prevention: vitamin D trials,” Science, vol. 338, no. 6109, p. 883, 883.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133